Innovative Drug Development Initiative (IDDI) Workstreams
The IDDI is a global, collaborative forum where representatives from academia, the pharmaceutical industry (established and emerging biotechnology), and drug regulators openly discuss questions surrounding the future of trials involving novel drugs. See our IDDI Special collection on Clinical Trial Design: Past, Present, and Future.
We believe in the power of early and ongoing dialogue with all stakeholders in the drug development process, including the crucial perspective of patients and their advocates. The IDDI aspires to explore novel approaches for combating and treating PVD and PH, focusing strongly on patient needs. There are eight IDDI Workstreams, each assigned to address various challenges PH patients face.
Meet the 2025 IDDI Leadership Team
Sidra M. Hoffman, Ph.D., is a multidisciplinary scientist and clinical development leader with expertise in fibrotic, vascular, and inflammatory-driven rare pulmonary diseases. Currently, she serves as Senior Director of Clinical Development at Gossamer Bio. Dr. Hoffman is recognised for her contributions to clinical and translational medicine and her leadership in academic-industry collaborations. She holds a Ph.D. in respiratory cell and molecular biology from Maastricht University and a certification in Medical Affairs and Medicines Development from King's College London.
Dr. Luke Howard is a Consultant Pulmonologist and Lead Clinician for the Pulmonary Hypertension Service, based at Hammersmith Hospital, Imperial College Healthcare NHS Trust. He is also Lead Clinician for Exercise Physiology services at Imperial College Healthcare. Areas of research interest include cardiopulmonary physiology, and early and late phase clinical trials, particularly in the field of Pulmonary Hypertension and Pulmonary Embolism. The Pulmonary Hypertension Service is one of the designated units in the National Pulmonary Hypertension Service which is a clinical and research network which aims to deliver excellent clinical outcomes and promote basic, translational and clinical research in the field of pulmonary vascular disease.
Dr. Gil Golden brings over 20 years of leadership in biopharma, with broad experience spanning product development, medical education, regulatory affairs, and corporate strategy. His work has supported drug, device, and biologics development from preclinical through Phase IV, often in collaboration with government, academic, and industry partners to address unmet medical needs. He currently oversees strategic contributions to all development phases and supports around 36 investigator-sponsored studies. Before joining United Therapeutics, he held executive roles at Guilford Pharmaceuticals, Pharmion, and Azur Pharma. Dr. Golden earned his Ph.D. in neuroendocrinology from the University of Pittsburgh and trained at the Medical College of Pennsylvania.
Dr. Sandeep Sahay is a pulmonary and critical care physician who leads the Pulmonary Hypertension Program at Houston Methodist Hospital and teaches as an Associate Professor at Weill Cornell Medicine. Originally from India, he trained at the Cleveland Clinic and UT Houston. Passionate about improving care for patients with pulmonary vascular diseases, he’s involved in leading clinical trials and shaping national and international guidelines. Dr. Sahay also plays an active role in medical education and mentoring. He’s received multiple awards for his work and continues to be driven by a deep commitment to research, teaching, and patient care.
Task Forces
Our Disease and Specialty Task Forces focus on research into specific areas of PVD. They support us in understanding and implementing our vision and mission. Our Regional Task Forces focus on the key challenges facing patients, clinicians and researchers in their country or region. Several Regional Task Forces were impacted by the Covid pandemic and are currently inactive, but some are in the process of re-forming, such as the South East Asia Task Force and China Task Force.
Find out more about each IDDI Workstream or Task Force below. PVRI members who are interested in contributing are encouraged to join.